Join to View Full Profile
40 Duke Medicine CirDurham, NC 27710
Phone+1 919-684-8111
Dr. Kang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2007
St Luke's HospitalInternship, Internal Medicine, 2004 - 2005- The Second Military Medicine UnivClass of 1985
Certifications & Licensure
NC State Medical License 2007 - 2025
SC State Medical License 2010 - 2025
IA State Medical License 2005 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma Start of enrollment: 2011 Aug 01
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- β-Arrestin 2 as a Prognostic Indicator and Immunomodulatory Factor in Multiple Myeloma.Parker Mathews, Xiaobei Wang, Jian Wu, Shaima Jabbar, Kimberly Burcher
Cells. 2025-03-26 - Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma.Zhannan Han, Zhibo Yan, Zhehan Ma, Yihui Wang, Maja Beus
Leukemia. 2025-03-01 - 3 citationsChromatin Remodeling in Patient-Derived Colorectal Cancer Models.Kun Xiang, Ergang Wang, John Mantyh, Gabrielle Rupprecht, Marcos Negrete
Advanced Science. 2024-04-01
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
RedHill Biopharma Announces Presentation on YELIVA® (Opaganib) for Multiple Myeloma at EORTC-NCI-AACR SymposiumNovember 14th, 2018
Grant Support
- Role of SLAMF7 in Racial Disparities in MyelomaDUKE UNIVERSITY2023–2025
- Enhancing CAR T therapy in multiple myelomaDUKE UNIVERSITY2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
